Solid Biosciences Inc.
$6.85
+4.1%Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -3.4).
Valuation inputs: P/E -3.4, earnings yield N/A, momentum +4.1%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -96.8%, ROIC -89.1%).
Profitability stack: net margin 0.0%, ROE -96.8%, ROIC -89.1%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +22.6%, momentum +4.1%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Solid Biosciences Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Solid Biosciences Inc. Fair Value Envelope
Solid Biosciences Inc. Profit Bridge
Profitability Analysis
Solid Biosciences Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Solid Biosciences Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Solid Biosciences Inc. Street Expectations Map
Wall Street analysts project that SLDB stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 16.67, with estimates ranging from a low of 16.00 to a high of 18.00.
The consensus 1-year price target stands at 16.67, with estimates ranging from a low of 16.00 to a high of 18.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Solid Biosciences Inc. Insider Positioning
During the last 12 months, insiders have purchased $3.19M and sold $2.68M worth of SLDB shares, resulting in $513K of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
398.5K
2.53M
-2.5M
-$2.53M
6-9 Months
0
0.00
29.1K
147.90K
-148K
-$148K
9-12 Months
697.5K
3.19M
0
0.00
+3.2M
+$3.19M
Top Buyers
Keresty Georgia
Director
$355K
Stone Adam Leo
Director
$355K
Sullivan Lynne Marie
Director
$355K
Ganot Ilan
Director
$355K
Kahn Clare
Director
$355K
Top Sellers
Cumbo Alexander
Director, Officer: President And Ceo
$984K
Howton David T
Officer: Chief Operating Officer
$434K
Tan Kevin
Officer: Cfo & Treasurer
$330K
Hanrahan Jessie
Officer: Chief Regulatory Officer
$297K
Brooks Gabriel
Officer: Chief Medical Officer
$281K
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $513K net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
No Dividend Yield Data
SLDB has not reported any dividend yield values in the available annual periods.
sldb Dividend History
Learning Layer
Related Guides
Build conviction on SLDB by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.